A new study suggests that helping brain cells repair their damaged DNA may one day become an effective treatment for Alzheimer’s disease.
Researchers from King’s College London reported in FEBS Open Bio that an experimental medicine called KCL-286 improved DNA repair and reduced harmful inflammation in mice with Alzheimer’s disease.
Alzheimer’s disease develops over many years. Scientists have traditionally focused on two abnormal proteins, amyloid and tau, because they build up in the brain as the disease progresses. However, researchers now believe many other biological changes also contribute, including inflammation, damage to nerve cells, and problems with DNA repair.
DNA acts as the instruction manual for every cell in the body. Although cells have natural repair systems, these systems become less effective with age. Brain cells are especially vulnerable because they are rarely replaced. When DNA damage accumulates over many years, neurons may lose their ability to communicate, leading to memory and thinking problems.
The new research examined whether strengthening these repair systems could protect the brain. The experimental drug KCL-286 activates a protein known as retinoic acid receptor-beta. This activation switches on genes that help repair damaged DNA inside neurons.
Using mice that develop Alzheimer’s-like changes, the researchers found that treated animals repaired more DNA damage than untreated animals. They also showed less inflammation and reduced activity of overactive immune cells in the brain. Since chronic inflammation is believed to worsen Alzheimer’s disease, lowering this inflammation may help slow further brain injury.
The researchers describe the treatment as fixing the underlying damage instead of only treating the consequences. Professor Jonathan Corcoran explained that repairing DNA is like repairing potholes in a road. Once the road is repaired, traffic can move normally again. Likewise, healthier neurons may communicate better once their DNA damage has been repaired.
The findings may have importance beyond Alzheimer’s disease. Many neurological disorders involve damaged nerve cells and long-term inflammation. If improving DNA repair protects neurons, similar approaches could potentially be explored for other degenerative brain diseases and nerve injuries.
Despite the encouraging findings, the research is still at an early stage. The study involved laboratory mice, so scientists cannot yet say whether patients with Alzheimer’s disease will experience the same benefits. Human biology is far more complex, and many experimental drugs fail during later testing.
One encouraging sign is that phase 1 clinical trials have already shown KCL-286 to be generally safe in humans. The next step is to carry out larger clinical trials to determine whether the drug can slow memory decline or improve quality of life for people living with Alzheimer’s disease.
This study provides a fresh perspective on Alzheimer’s treatment by targeting DNA repair instead of focusing entirely on amyloid and tau proteins. Its strengths include a well-defined biological mechanism and encouraging preclinical results.
However, its greatest limitation is the lack of human effectiveness data. Future clinical trials will determine whether repairing DNA damage can truly change the course of Alzheimer’s disease.
If you care about Alzheimer’s disease, please read studies that bad lifestyle habits can cause Alzheimer’s disease, and strawberries can be good defence against Alzheimer’s.
For more information about brain health, please see recent studies that oral cannabis extract may help reduce Alzheimer’s symptoms, and Vitamin E may help prevent Parkinson’s disease.
Source: King’s College London.
